Taking a novel approach to drug development
Lantern’s drug development approach is innovative. From the novel small molecule compounds in our portfolio, to our targeted, rare patient populations who will benefit from these drugs, our pending and issued patent portfolio reflects our unique precision oncology focus.
Pending Patent Applications
General Application
Next Generation Illudins
Patent Title
Illudin Analogs, Used Thereof, and Methods for Synthesizing the Same
Patent Summary
This application covers illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof. A new and potentially more potent illudin is disclosed in this application. A more effective and efficient manufacturing scheme is also disclosed in this application.
Patent No./Application No.
62726914
Countries
US and other countries TBD
Priority of Filing Date
9/4/18
General Application
RADR Applications
Patent Title
Anticancer Drug Sensitivity-Determining Markers
Patent Summary
This application covers a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins) to be administered thereto, which marker can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the marker. Also included is a method for determining sensitivity of a subject having cancer to a illudin-based anti-cancer agent, the method includes measuring a level or presence of PTGR1 and at least one other gene.
Patent No./Application No.
62745382
Countries
US and other countries TBD
Priority of Filing Date
10/14/18
General Application
Female Non-Smokers with Non-Small Cell Lung Cancer Treatment
Patent Title
Method for Treating Female Non Smokers with Non-Small Cell Lung Cancer
Patent Summary
his application covers a method for increasing survival time in a female patient with non-small cell lung carcinoma or non-small cell lung carcinoma in which 2,2′-dithio-bis-ethane sulfonate or salt is administered in a therapeutically effective amount to the patient with non-small cell lung carcinoma.
Patent No./Application No.
62815762
Countries
US and other countries TBD
Priority of Filing Date
3/8/19
General Application
PTGR1 Application
Patent Title
PTGR1 Sensitivity and Acylfulvene Efficacy in Cancer Treatments
Patent Summary
This application covers methods and materials for identifying and treating candidate patients with acylfulvenes.
Patent No./Application No.
62852913
Countries
US and other countries TBD
Priority of Filing Date
5/24/19
General Application
Tavocept®
Patent Title
Contemporaneous, Multiple Protein-Targeted Therapeutic Modification and/or Modulation of Disease by Administration of Sulfur-Containing, Amino Acid-Specific Small Molecules
Patent Summary
A method for the contemporaneous, heterogeneously-oriented metabolic modification and/or modulation of the expression level of multiple target molecules; wherein any combination of target molecules is selected from the group consisting of: anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition (MET) kinase, the receptor tyrosine kinase (ROS1), epidermal growth factor receptor (EGFR), peroxiredoxin (Prx), excision repair cross-complementing protein 1 (ERCC1), insulin growth factor 1 receptor (IGF1R), ribonucleotide reductase, tubulin, farnesyltransferase, and other target molecules possessing a similar active site or structural motif.
Patent No./Application No.
14455855
Countries
US
Priority of Filing Date
8/8/14
General Application
Tavocept®
Patent Title
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
Patent Summary
This application covers a method for (i) increasing patient survival time; (ii) promoting the arrest or retardation of tumor progression; (iii) concomitantly maintaining or increasing the quality of life in a cancer patient; and/or (iv) potentiating the cytotoxic/cytostatic effects of a chemotherapy agent or agents used to treat a patient suffering from cancer.
Patent No./Application No.
14675607 (Issue Fee Paid)
Countries
US
Priority of Filing Date
9/16/10
Issued Patents
General Application
Tavocept®
Patent Title
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
Patent Summary
This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions
Patent No./Application No.
US9023805
Countries
US
Priority of Filing Date
9/16/10
General Application
Tavocept®
Patent Title
Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions
Patent Summary
This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions
Patent No./Application No.
US9320760
Countries
Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US
Priority of Filing Date
7/15/08
General Application
Tavocept®
Patent Title
Medicinal Disulfide Salts
Patent Summary
This patent is directed to various medicinal disulfide salts
Patent No./Application No.
US7282602
Countries
Canada, Japan, Mexico, and US
Priority of Filing Date
9/21/04
General Application
Tavocept®
Patent Title
Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions
Patent Summary
This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions
Patent No./Application No.
US9320760
Countries
Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US
Priority of Filing Date
7/15/08
General Application
Tavocept®
Patent Title
Chemoprotective Methods and Compositions
Patent Summary
Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.
Patent No./Application No.
CA2648945
Countries
Australia, Canada, China, Denmark, France, Germany, Hungary, Ireland, Italy, Japan, Netherlands, Sweden, Switzerland, and UK
Priority of Filing Date
12/13/06
General Application
Tavocept®
Patent Title
Process for Synthesizing Disulfides
Patent Summary
This patent discloses a process for producing a substantially pure disulfide , such as disodium 2,2_-dithiobis ethane sulfonate, by an efficient procedure from available, relatively inexpensive raw materials.
Patent No./Application No.
US7053240
Countries
Australia, Canada, China
Priority of Filing Date
12/17/04
General Application
Tavocept®
Patent Title
Method of Treating Patients Undergoing Kidney Dialysis
Patent Summary
This invention relates to a method of treating patients who are receiving dialysis treatments. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
Patent No./Application No.
US7235589
Countries
France, UK and US
Priority of Filing Date
9/21/05
General Application
Tavocept®
Patent Title
Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents
Patent Summary
The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Patent No./Application No.
US Patent Nos. 7829540, 7829539, 7829117, 7829538 & 7235589
Countries
France, UK and US
Priority of Filing Date
11/14/07
General Application
Tavocept®
Patent Title
Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate
Patent Summary
Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate
Patent No./Application No.
US6936733
Countries
Australia, Belgium, France, Germany, Ireland, Italy, Japan, Sweden, Switzerland, UK and US
Priority of Filing Date
7/17/01
General Application
Tavocept®
Patent Title
Drugs for Prophylaxis or Mitigation of Taxane-Induced Neuropathies
Patent Summary
This Patent covering treating taxane neuropathy with 2,2_-dithiobis ethane sulfonate
Patent No./Application No.
US8710095
Countries
Australia, France, Germany, Japan, Spain, Sweden, Switzerland, UK and US
Priority of Filing Date
4/30/02
General Application
Tavocept®
Patent Title
Process for Synthesizing Pharmaceutically Active Disulfide Salts
Patent Summary
This patent covers a process for synthesizing pharmaceutically active disulfide or thiol-containing compound
Patent No./Application No.
US6504049
Countries
Australia, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Netherlands, Spain, Sweden, Switzerland, UK and US
Priority of Filing Date
5/30/02
General Application
Other Applications
Patent Title
Method for Treating Patients for Radiation Exposures
Patent Summary
This patent covers treating patents for radiation exposure with disulfide or thiol-containing compound.
Patent No./Application No.
US7176192
Countries
US
Priority of Filing Date
10/26/01
General Application
Tavocept®
Patent Title
Method for Treating Cancer Having Greater Efficacy and Reduced Adverse Effects
Patent Summary
This patent covers reducing side effects with disulfide or thiol-containing compound .
Patent No./Application No.
US6596320
Countries
US
Priority of Filing Date
1/11/02
General Application
Tavocept®
Patent Title
Methods and Formulations for Reducing Toxicity Associated with Diabetes Treatments
Patent Summary
This patent covers reducing side effects from diabetes treatments with disulfide or thiol-containing compound .
Patent No./Application No.
US6468963
Countries
US
Priority of Filing Date
5/1/00
General Application
Tavocept®
Patent Title
Method of Inhibiting Angiogenesis
Patent Summary
This patent covers inhibiting angiogenesis with disulfide salts.
Patent No./Application No.
US6255355
Countries
US
Priority of Filing Date
1/6/01
General Application
Tavocept®
Patent Title
Method of Treating Acetaminophen Overdose
Patent Summary
This patent covers treating acetaminophen overdose with disulfide or thiol-containing compound .
Patent No./Application No.
US6225295
Countries
US
Priority of Filing Date
9/27/00
General Application
Tavocept®
Patent Title
Method of Treating Atherosclerosis and Complications Resulting Therefrom.
Patent Summary
Method of Treating Atherosclerosis and Complications using disulfide or thiol-containing compound.
Patent No./Application No.
US6525037
Countries
US
Priority of Filing Date
2/25/00
General Application
Tavocept®
Patent Title
Method of Treating Diabetic Nephropathy
Patent Summary
Method of Treating Diabetic Nephropathy with disulfide or thiol-containing compound
Patent No./Application No.
US6031006 & US6100247
Countries
US
Priority of Filing Date
10/21/99
General Application
Tavocept®
Patent Title
Method for Reducing Development of Free Radical Induced Malignancies
Patent Summary
Method for Reducing Development of Free Radical Induced Malignancies
Patent No./Application No.
US6143796
Countries
US
Priority of Filing Date
9/2/99
General Application
Tavocept®
Patent Title
Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof
Patent Summary
Methods for augmentation of anti-cancer activity
Patent No./Application No.
China ZL200780017354
Countries
China, Australia
Priority of Filing Date
3/16/07
General Application
Tavocept®
Patent Title
Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents
Patent Summary
The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Patent No./Application No.
US7176192
Countries
Australia
Priority of Filing Date
10/26/01
General Application
Tavocept®
Patent Title
Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents
Patent Summary
The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
Patent No./Application No.
US7176192
Countries
Australia
Priority of Filing Date
10/26/01
General Application
Irofulven
Patent Title
Illudin Analogs Useful as Anticancer Agents
Patent Summary
Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment
Patent No./Application No.
US7655695
Countries
EP1909783B1 (Germany, France, and Great Britain), JP4989648 (US is Priority Application)
Priority of Filing Date
2/2/10
General Application
Irofulven
Patent Title
Antitumor Agents
Patent Summary
Various Acylfulvene analogs with various R groups thereon
Patent No./Application No.
US7141603
Countries
US Only
Priority of Filing Date
11/28/06
Let’s start a conversation about the future of cancer drug development.
We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.